SciVision Biotech Inc. (TPE:1786)
Taiwan · Delayed Price · Currency is TWD 79.80
+0.60 (0.76%)
Jan 22, 2026, 1:35 PM CST
SciVision Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Net Income | 164.72 | 242.25 | 177.9 | 141.72 | 101.72 | 128.01 | Upgrade |
Depreciation & Amortization | 76.32 | 65.14 | 63.05 | 62.02 | 52.98 | 15.27 | Upgrade |
Other Amortization | 0.07 | 0.08 | 0.08 | 0.04 | 0.04 | 0.04 | Upgrade |
Loss (Gain) From Sale of Assets | - | -0.19 | -0.54 | -30.55 | -0.13 | - | Upgrade |
Loss (Gain) From Sale of Investments | 0.38 | -6.45 | -2.9 | 1.98 | 0.13 | -4.36 | Upgrade |
Other Operating Activities | 7.56 | 25.99 | 7.43 | 18.12 | -2.23 | 10.73 | Upgrade |
Change in Accounts Receivable | -15.57 | -73.55 | -4.85 | -7.77 | -10.47 | -6.74 | Upgrade |
Change in Inventory | -6.58 | 14.45 | 8.62 | -13 | -37.03 | -12.68 | Upgrade |
Change in Accounts Payable | 8.38 | 6.52 | -3.21 | 6.77 | -11.33 | 4.81 | Upgrade |
Change in Unearned Revenue | -4.98 | -4.34 | 6.32 | -1.01 | -5.6 | -4.53 | Upgrade |
Change in Other Net Operating Assets | 7.52 | -0.04 | 20.11 | 3.68 | 10.41 | -4.09 | Upgrade |
Operating Cash Flow | 237.81 | 269.87 | 272.01 | 181.99 | 98.51 | 126.47 | Upgrade |
Operating Cash Flow Growth | -5.16% | -0.79% | 49.47% | 84.75% | -22.11% | -38.13% | Upgrade |
Capital Expenditures | -91.82 | -34.76 | -14.73 | -14.96 | -25.78 | -66.84 | Upgrade |
Sale of Property, Plant & Equipment | - | 0.19 | 1.26 | 56.48 | 21.13 | - | Upgrade |
Sale (Purchase) of Intangibles | -0.23 | -0.12 | -0.11 | - | - | - | Upgrade |
Investment in Securities | 20.21 | 134 | -201.79 | -48.49 | -20.89 | 86.01 | Upgrade |
Other Investing Activities | -4.81 | -1.79 | 2.01 | 52.79 | -51.47 | 1.2 | Upgrade |
Investing Cash Flow | -76.65 | 97.52 | -213.37 | 45.81 | -77.01 | 20.37 | Upgrade |
Short-Term Debt Issued | - | - | - | - | 10 | 230 | Upgrade |
Long-Term Debt Issued | - | - | - | 700 | 1,200 | - | Upgrade |
Total Debt Issued | 402 | - | - | 700 | 1,210 | 230 | Upgrade |
Short-Term Debt Repaid | - | - | - | - | -10 | -230 | Upgrade |
Long-Term Debt Repaid | - | -3.35 | -1.23 | -905.89 | -901.39 | -1.27 | Upgrade |
Total Debt Repaid | -8.26 | -3.35 | -1.23 | -905.89 | -911.39 | -231.27 | Upgrade |
Net Debt Issued (Repaid) | 393.74 | -3.35 | -1.23 | -205.89 | 298.61 | -1.27 | Upgrade |
Common Dividends Paid | -233.87 | -169.33 | -133.3 | -93.83 | -58.56 | -79.26 | Upgrade |
Other Financing Activities | 0.16 | 0.16 | - | 0.01 | - | - | Upgrade |
Financing Cash Flow | 160.04 | -172.52 | -134.53 | -299.71 | 240.06 | -80.53 | Upgrade |
Foreign Exchange Rate Adjustments | -0.1 | 0.05 | -0.03 | 0.01 | -0.01 | 0.01 | Upgrade |
Net Cash Flow | 321.1 | 194.92 | -75.92 | -71.9 | 261.55 | 66.32 | Upgrade |
Free Cash Flow | 145.99 | 235.11 | 257.28 | 167.03 | 72.73 | 59.63 | Upgrade |
Free Cash Flow Growth | -34.59% | -8.62% | 54.04% | 129.64% | 21.97% | 1573.65% | Upgrade |
Free Cash Flow Margin | 16.39% | 26.62% | 36.08% | 29.97% | 14.39% | 12.77% | Upgrade |
Free Cash Flow Per Share | 1.98 | 3.16 | 3.37 | 2.24 | 1.02 | 0.84 | Upgrade |
Cash Interest Paid | 0.71 | 0.99 | 0.42 | 2.99 | 1.12 | 0.75 | Upgrade |
Cash Income Tax Paid | 25.73 | 28.6 | 30.97 | 11.51 | 23.53 | 19.95 | Upgrade |
Levered Free Cash Flow | 47.6 | 134.06 | 189.21 | 99.15 | 9.36 | -14.43 | Upgrade |
Unlevered Free Cash Flow | 51.51 | 137.61 | 194.35 | 103.18 | 14.4 | -9.76 | Upgrade |
Change in Working Capital | -11.23 | -56.96 | 26.99 | -11.33 | -54.01 | -23.22 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.